News | February 19, 2025
Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Immedica to commence a cash tender offer to acquire all issued and outstanding shares of Marinus for an enterprise value of approximately US$ 151 million
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
This Fast Track Designation will enable FDA to review MM-II in an expedited manner, is an important milestone in the development of MM-II
Winrevair is the first activin signaling inhibitor therapy for PAH approved in Europe
Dr. Reddy's had previously received the EU GMP certificate for its Rituximab drug substance
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Additional data from APPRAISE ATP trial reinforce modular therapy approach
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Subscribe To Our Newsletter & Stay Updated
